Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I2XM
|
||||
| Former ID |
DNC010594
|
||||
| Drug Name |
L-796568
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Obesity [ICD9: 278; ICD10:E66] | Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C31H27F3N4O3S2
|
||||
| Canonical SMILES |
C1=CC(=CN=C1)C(CNCCC2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)<br />C4=NC(=CS4)C5=CC=C(C=C5)C(F)(F)F)O.Cl.Cl
|
||||
| InChI |
1S/C31H27F3N4O3S2.2ClH/c32-31(33,34)25-9-5-22(6-10-25)28-20-42-30(37-28)23-7-13-27(14-8-23)43(40,41)38-26-11-3-21(4-12-26)15-17-36-19-29(39)24-2-1-16-35-18-24;;/h1-14,16,18,20,29,36,38-39H,15,17,19H2;2*1H/t29-;;/m0../s1
|
||||
| InChIKey |
CANSTXQBARAFMV-UJXPALLWSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Beta-2 adrenergic receptor | Target Info | Inhibitor | [2] | |
| Beta-1 adrenergic receptor | Target Info | Inhibitor | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Salivary secretionhsa04020:Calcium signaling pathway | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta2 adrenergic receptor signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Beta1 adrenergic receptor signaling pathway | |||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| Arf6 signaling events | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling eventsR-HSA-390696:Adrenoceptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Vitamin D Receptor Pathway | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP58:Monoamine GPCRs | |||||
| Endothelin Pathways | |||||
| References | |||||
| REF 1 | Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002 Oct;76(4):780-8. | ||||
| REF 2 | Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. Epub 2010 Feb 4.Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.